Share Repurchase Program Initiated by Becton, Dickinson and Company (NYSE:BDX) Board

Becton, Dickinson and Company (NYSE:BDX) declared that its board has authorized a stock repurchase program on Tuesday, January 27th, RTT News reports. The company plans to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Bank of America upped their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Jefferies Financial Group lifted their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Morgan Stanley boosted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Trading Down 0.0%

Shares of NYSE BDX traded down $0.01 during midday trading on Tuesday, hitting $203.41. 1,884,824 shares of the company traded hands, compared to its average volume of 1,491,532. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The firm has a market cap of $57.95 billion, a P/E ratio of 34.89, a P/E/G ratio of 2.25 and a beta of 0.23. The stock has a 50-day moving average price of $197.87 and a 200 day moving average price of $190.90. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. During the same period in the prior year, the firm earned $3.81 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were given a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,605 shares of company stock worth $524,643 in the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.